Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CAMP
stocks logo

CAMP

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2024Q4
FY2025Q1
53.00M
-32.49%
-2.070
-250%
54.00M
-23.83%
-1.610
-1420.75%
Estimates Revision
The market is revising No Change the revenue expectations for CalAmp Corp. (CAMP) for FY2024, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 123.03%.
Revenue Estimates for FY2024
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2024
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+123.03%
In Past 3 Month
Wall Street analysts forecast CAMP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CAMP is 15.25 USD with a low forecast of 8.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast CAMP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CAMP is 15.25 USD with a low forecast of 8.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.390
sliders
Low
8.00
Averages
15.25
High
18.00
Current: 3.390
sliders
Low
8.00
Averages
15.25
High
18.00
Canaccord
initiated
$10
2025-12-03
New
Reason
Canaccord
Price Target
$10
2025-12-03
New
initiated
Reason
As previously reported, Canaccord initiated coverage of Compass Therapeutics with a Buy rating and $10 price target, telling investors that the firm expects positive data during Q1 0f 2026 for the company's lead asset tovecimig in second-line biliary tract carcinoma. Compass also has two additional assets in the clinic, both of which have shown activity in solid tumors, potentially diversifying revenues long term, the analyst added.
Cantor Fitzgerald
Li Watsek
Overweight
initiated
2025-12-03
New
Reason
Cantor Fitzgerald
Li Watsek
Price Target
2025-12-03
New
initiated
Overweight
Reason
Cantor Fitzgerald analyst Li Watsek initiated coverage of Compass Therapeutics with an Overweight rating and no price target. The company is is approaching readouts for its lead bispecific antibody, tovecimig, in late Q1, the analyst tells investors in a research note. Cantor believes the stock "has an asymmetrical setup" into the readout. It believes the Street underestimates the peak sales of tovecimig in second-line biliary tract cancer, which it thinks could reach $712M by 2032.
JPMorgan
Anupam Rama
Overweight -> Neutral
downgrade
2025-09-16
Reason
JPMorgan
Anupam Rama
Price Target
2025-09-16
downgrade
Overweight -> Neutral
Reason
JPMorgan analyst Anupam Rama downgraded Camp4 Therapeutics to Neutral from Overweight without a price target. The company's private placement provides a cash runway into 2027, but this is balanced by its the lead program CMP-SYNGAP-01 for Syngap-related disorders being in the very early stage, the analyst tells investors in a research note. JPMorgan now sees a long time horizon to patient level value creation for the shares.
Piper Sandler
Edward Tenthoff
Overweight
downgrade
$18 -> $12
2025-09-15
Reason
Piper Sandler
Edward Tenthoff
Price Target
$18 -> $12
2025-09-15
downgrade
Overweight
Reason
Piper Sandler analyst Edward Tenthoff lowered the firm's price target on Camp4 Therapeutics to $12 from $18 and keeps an Overweight rating on the shares. The firm notes Camp4 recently raised $50M bringing pro-form cash to about $86.1M to fund operations into 2027. Participating investors agreed to purchase an additional $50M upon acceptance of the CTA for CPS-SYNGAP-01, which Piper expects in the second half of 2026. The firm is lowering its price target on the shares by increasing value for CMP-SYNGAP-01, reducing value for CMP-CPS-001 and factoring dilution from the recent financing.
Wedbush
NULL -> Outperform
initiated
$8
2025-05-27
Reason
Wedbush
Price Target
$8
2025-05-27
initiated
NULL -> Outperform
Reason
Wedbush initiated coverage of Camp4 Therapeutics with an Outperform rating and $8 price target.
Wedbush
Yun Zhong
Outperform
initiated
$8
2025-05-27
Reason
Wedbush
Yun Zhong
Price Target
$8
2025-05-27
initiated
Outperform
Reason
Wedbush analyst Yun Zhong initiated coverage of Camp4 Therapeutics with an Outperform rating and $8 price target. The company's lead candidate CMP-CPS-01 increases the expression of an enzyme for the treatment of urea cycle disorders that affect approximately 20,000 U.S. and European Union patients with no disease modifying treatments available, the analyst tells investors in a research note. The firm says preclinical data show efficient and sustained reduction of ammonia, the root cause of all disease symptoms, and increased expression of additional urea cycle enzymes as well, suggesting approximately 90% of urea cycle disorders patients will be eligible for treatment. Wedbush's calculation suggests approximately 2,000 such patients in the U.S., indicating a $1B opportunity.
See All Ratings

Valuation Metrics

The current forward P/E ratio for CAMP4 Therapeutics Corp (CAMP.O) is 0.04, compared to its 5-year average forward P/E of 7.02. For a more detailed relative valuation and DCF analysis to assess CAMP4 Therapeutics Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
7.02
Current PE
0.04
Overvalued PE
151.40
Undervalued PE
-137.36

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average EV/EBITDA
15.77
Current EV/EBITDA
8.16
Overvalued EV/EBITDA
20.69
Undervalued EV/EBITDA
10.86

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PS
0.61
Current PS
0.00
Overvalued PS
1.10
Undervalued PS
0.13
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

CAMP News & Events

Events Timeline

(ET)
2025-10-01
08:09:47
Camp4 Therapeutics Begins GLP Toxicology Studies for CMP-SYNGAP-01
select
2025-09-10 (ET)
2025-09-10
07:12:16
Camp4 Therapeutics names Doug Williams as board chair and Dan Tardiff as Chief Scientific Officer.
select
2025-09-10
07:11:28
Camp4 Therapeutics Reveals Successful Oversubscribed Private Placement of Up to $100 Million
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-26Globenewswire
Camposol Reports 21% Sales Growth in Q3 2025 and Opens New Blueberry Biofactory
  • Significant Sales Growth: Camposol achieved sales of $367 million in the first nine months of 2025, reflecting a 21% year-over-year increase, indicating strong demand in the global fresh food market and an increase in market share.
  • Blueberry Volume Surge: The company reported a 62.8% year-over-year increase in blueberry volumes, reaching 36.5 thousand MT with sales of $242.2 million, showcasing success in product diversification and market adaptability.
  • New Factory Launch: Camposol inaugurated a new 2,000 m² blueberry biofactory in Chao, Virú, with an annual capacity of up to 5 million plants, enhancing genetic development capabilities and supporting future planting plans, thereby improving long-term competitiveness.
  • Financial Stability: The company's net debt-to-EBITDA ratio stands at 2.81, remaining below the 3.5 threshold for five consecutive quarters, demonstrating ongoing progress in financial management and deleveraging, which bolsters investor confidence.
[object Object]
Preview
5.0
11-19NASDAQ.COM
5AM Venture Sells Its Viking Stake—Wise Decision or Lost Chance?

  • 5AM Venture Management's Exit: The firm completely liquidated its position in Viking Therapeutics, selling 189,593 shares for an estimated net position change of $5.02 million, reducing its stake from 1.9% to zero as of Q3 2025.

  • Market Performance: As of November 18, 2025, Viking Therapeutics shares were priced at $38.00, down 5.6% year-to-date, underperforming the S&P 500 by 18.7 percentage points.

  • Investment Perspective: The sale is viewed as a rebalancing strategy rather than a lack of confidence in Viking's drug development, emphasizing the long-term nature of investing in clinical-stage biopharmaceuticals.

  • Investor Insights: The article highlights that individual investors in development-stage biotech must be patient and resilient, as stock movements are primarily driven by clinical data rather than trading activity.

[object Object]
Preview
5.0
11-19NASDAQ.COM
5AM Venture Exits MoonLake Following a Challenging Year: Key Highlights to Note

  • 5AM Venture Management's Exit: The fund sold its entire stake in MoonLake Immunotherapeutics, liquidating 282,313 shares for an estimated $13.33 million, which previously represented 5.12% of its assets.

  • Stock Performance: Following the sale, MoonLake's shares were priced at $13.58, reflecting a 74.9% decline over the past year and significantly underperforming the S&P 500.

  • Risk Management Strategy: The decision to exit the investment is seen as a move to reduce risk amid the stock's poor performance, indicating a shift towards more stable investments.

  • Clinical Development Focus: MoonLake's future hinges on the success of its main drug, sonelokimab, with investor sentiment likely to fluctuate based on clinical trial outcomes and milestones.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is CAMP4 Therapeutics Corp (CAMP) stock price today?

The current price of CAMP is 3.39 USD — it has increased 4.31 % in the last trading day.

arrow icon

What is CAMP4 Therapeutics Corp (CAMP)'s business?

CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a range of genetic diseases. It is leveraging its RAP Platform to advance a pipeline of programs focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.

arrow icon

What is the price predicton of CAMP Stock?

Wall Street analysts forecast CAMP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CAMP is 15.25 USD with a low forecast of 8.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is CAMP4 Therapeutics Corp (CAMP)'s revenue for the last quarter?

CAMP4 Therapeutics Corp revenue for the last quarter amounts to 858.00K USD, decreased -98.79 % YoY.

arrow icon

What is CAMP4 Therapeutics Corp (CAMP)'s earnings per share (EPS) for the last quarter?

CAMP4 Therapeutics Corp. EPS for the last quarter amounts to -0.62 USD, increased 463.64 % YoY.

arrow icon

What changes have occurred in the market's expectations for CAMP4 Therapeutics Corp (CAMP)'s fundamentals?

The market is revising No Change the revenue expectations for CalAmp Corp. (CAMP) for FY2024, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 123.03%.
arrow icon

How many employees does CAMP4 Therapeutics Corp (CAMP). have?

CAMP4 Therapeutics Corp (CAMP) has 55 emplpoyees as of December 05 2025.

arrow icon

What is CAMP4 Therapeutics Corp (CAMP) market cap?

Today CAMP has the market capitalization of 660.34K USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free